Alembic Pharmaceuticals witnessed a notable rise in its share price, surging by 3.63% to hit an intraday high of ₹1,235.95 per share on Monday, 30 September 2024. This increase followed a positive development from the United States Food and Drug Administration (USFDA), which issued an Establishment Inspection Report (EIR) after inspecting the company’s Oral Solid Formulation Facility (F-I). The growth in Alembic's shares has further solidified the company's standing in the share market investment sector.
USFDA report drives share price surge
The rise in Alembic Pharmaceuticals’ share price came after the USFDA released an EIR for its Oral Solid Formulation Facility (F-I). The inspection was conducted between 17 and 26 July 2024. This report acts as a positive indicator for the company, signalling compliance with the required regulatory standards in the pharmaceutical sector. Alembic Pharmaceuticals promptly communicated the news in a filing to the stock exchange, which was likely a key factor in boosting investor confidence, reflected in the rise in the company's share price.
Strong financial performance for Q1 FY25
The company's robust financial performance for the first quarter of FY25 also played a role in the share price movement. Alembic Pharmaceuticals reported a 12% year-on-year (Y-o-Y) increase in consolidated net profit, reaching ₹135 crore for Q1 FY25, compared to ₹121 crore in Q1 FY24. In addition, the company’s total income rose from ₹1,498 crore in Q1 FY24 to ₹1,564 crore in Q1 FY25.
These strong financial results have reinforced investor confidence, contributing to the continued upward trend in Alembic’s stock value. The combination of favourable regulatory feedback and strong earnings results has made the stock an attractive option for share market investment.
Share price performance year-to-date
Alembic Pharmaceuticals has demonstrated impressive performance in the stock market throughout 2024. The company's share price has jumped approximately 60% year-to-date (Y-T-D), marking a substantial gain. Over the last six months, the stock has rallied by more than 21%, highlighting its sustained growth. In just the past month, the stock has surged by about 14%, while in the last five days alone, it has gained over 6%.
These numbers reflect a positive trend for Alembic Pharmaceuticals, positioning the company as one of the stronger performers in the pharmaceutical sector this year.
Alembic Pharmaceuticals’ background
Alembic Pharmaceuticals Limited, headquartered in Vadodara, Gujarat, is a prominent name in the pharmaceutical industry. The company specialises in the production and marketing of formulations for both domestic and international markets. Its products range from generic formulations produced in Sikkim to active pharmaceutical ingredients (APIs) manufactured at its facilities in Gujarat.
Alembic has expanded its global footprint through subsidiaries such as Alembic Pharmaceuticals Inc. and Alembic Global Holding SA. It also operates research and development centres in Vadodara, Hyderabad, and New Jersey, emphasising its commitment to innovation and global healthcare solutions.
Outlook
At 11:20 a.m. on 30 September 2024, Alembic Pharmaceuticals’ shares were trading 2.88% higher at ₹1,227.05 per share, compared to a broader market decline, with the BSE Sensex trading 0.93% lower at 84,778.70 points. This rise in Alembic's stock reflects both the positive impact of the USFDA report and the company's strong quarterly performance.
Investors and analysts will continue to monitor Alembic Pharmaceuticals’ performance in the coming months, especially as the company strengthens its global presence and continues to receive regulatory approvals for its facilities and products.
For android only